Rabbit Recombinant Monoclonal TRIM8 antibody. Carrier free. Suitable for Flow Cyt (Intra), WB, IP and reacts with Human, Mouse, Rat samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
Flow Cyt (Intra) | WB | IP | IHC-P | ICC/IF | |
---|---|---|---|---|---|
Human | Tested | Tested | Tested | Not recommended | Not recommended |
Mouse | Expected | Tested | Expected | Not recommended | Not recommended |
Rat | Expected | Tested | Expected | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
E3 ubiquitin-protein ligase that participates in multiple biological processes including cell survival, differentiation, apoptosis, and in particular, the innate immune response (PubMed:27981609, PubMed:28747347). Participates in the activation of interferon-gamma signaling by promoting proteasomal degradation of the repressor SOCS1 (PubMed:12163497). Plays a positive role in the TNFalpha and IL-1beta signaling pathways. Mechanistically, induces the 'Lys-63'-linked polyubiquitination of MAP3K7/TAK1 component leading to the activation of NF-kappa-B (PubMed:22084099, PubMed:23152791, PubMed:27981609, PubMed:34871740). Modulates also STAT3 activity through negative regulation of PIAS3, either by degradation of PIAS3 through the ubiquitin-proteasome pathway or exclusion of PIAS3 from the nucleus (PubMed:20516148). Negatively regulates TLR3/4-mediated innate immune response by catalyzing 'Lys-6'- and 'Lys-33'-linked polyubiquitination of TICAM1 and thereby disrupting the TICAM1-TBK1 interaction (PubMed:28747347).
GERP, RNF27, TRIM8, E3 ubiquitin-protein ligase TRIM8, Glioblastoma-expressed RING finger protein, RING finger protein 27, RING-type E3 ubiquitin transferase TRIM8, Tripartite motif-containing protein 8
Rabbit Recombinant Monoclonal TRIM8 antibody. Carrier free. Suitable for Flow Cyt (Intra), WB, IP and reacts with Human, Mouse, Rat samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
ab316150 is the carrirer-free version of Anti-TRIM8 antibody [EPR27965-6] ab316149.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
TRIM8 also known as Tripartite Motif Containing 8 is an E3 ubiquitin ligase with a known mass of about 61 kDa. This protein facilitates protein degradation via the ubiquitin-proteasome system. It localizes to the nucleus and cytoplasm and is expressed in various tissues such as the brain and immune cells. TRIM8 influences multiple cellular processes by adding ubiquitin chains to specific proteins thereby tagging them for degradation.
TRIM8 is involved in the regulation of signaling pathways and acts as a modulator of cellular functions. TRIM8 participates in the stability and turnover of p53 and STAT3 affecting their transcriptional activities. It also contributes to immune responses by modulating pathways that involve interferon signaling. TRIM8 is not typically part of large protein complexes; its interactions often involve single protein-protein connections.
TRIM8 plays significant roles in immune signaling and apoptosis regulation. It interacts with the NF-kB pathway influencing inflammation and immune responses. Through this pathway TRIM8 impacts the activation of transcriptional activity affecting cellular survival and proliferation. Additionally TRIM8 interacts with proteins like p53 altering its function in the apoptotic pathway thereby influencing cell cycle regulation and survival.
TRIM8 has connections to cancer and neurodegenerative diseases. For cancer abnormalities in TRIM8 expression levels can result in altered p53 activity promoting tumor growth or suppression. In neurodegenerative contexts TRIM8's interaction with STAT3 can affect inflammatory responses linked to diseases like Alzheimer's. These relationships highlight the importance of TRIM8 in both the progression and inhibition of certain pathologies through its interactions with proteins such as p53 and STAT3.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-TRIM8 antibody [EPR27965-6] ab316149, the same antibody clone in a different buffer formulation.
TRIM8 was immunoprecipitated from 0.35 mg HCT 116 (human colorectal carcinoma epithelial cell) whole cell lysate with Anti-TRIM8 antibody [EPR27965-6] ab316149 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using Anti-TRIM8 antibody [EPR27965-6] ab316149 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: HCT 116 (human colorectal carcinoma epithelial cell) whole cell lysate
Lane 2: Anti-TRIM8 antibody [EPR27965-6] ab316149 IP in HCT 116 (human colorectal carcinoma epithelial cell) whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-TRIM8 antibody [EPR27965-6] ab316149 in HCT 116 whole cell lysate
All lanes: Immunoprecipitation - Anti-TRIM8 antibody [EPR27965-6] (Anti-TRIM8 antibody [EPR27965-6] ab316149) at 1/30 dilution
All lanes: HCT 116 (human colorectal carcinoma epithelial cell) whole cell lysate with 5% NFDM/TBST
All lanes: Immunoprecipitation - VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) at 1/5000 dilution
Exposure time: 102s
This data was developed using Anti-TRIM8 antibody [EPR27965-6] ab316149, the same antibody clone in a different buffer formulation.
All lanes: Western blot - Anti-TRIM8 antibody [EPR27965-6] (Anti-TRIM8 antibody [EPR27965-6] ab316149) at 1/1000 dilution
Lane 1: Mouse brain lysate at 20 µg with 5% NFDM/TBST
Lane 2: Rat brain lysate at 20 µg with 5% NFDM/TBST
Lane 3: Rat spleen lysate at 20 µg with 5% NFDM/TBST
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Observed band size: 61 kDa
Exposure time: 180s
This data was developed using Anti-TRIM8 antibody [EPR27965-6] ab316149, the same antibody clone in a different buffer formulation.
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.
All lanes: Western blot - Anti-TRIM8 antibody [EPR27965-6] (Anti-TRIM8 antibody [EPR27965-6] ab316149) at 1/1000 dilution
Lane 1: HCT 116 (human colorectal carcinoma epithelial cell) transfected with scrambled siRNA control whole cell lysate at 20 µg with 5% NFDM/TBST
Lane 2: HCT 116 transfected with siRNA specifically targeting TRIM8 whole cell lysate at 20 µg with 5% NFDM/TBST
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Observed band size: 61 kDa, 36 kDa
Exposure time: 92s
This data was developed using Anti-TRIM8 antibody [EPR27965-6] ab316149, the same antibody clone in a different buffer formulation.
Lysates were freshly made and used for Western blotting immediately to minimize protein degradation.
The identity of the higher MW band at approximately 90 kDa (in lane 4) is unknown.
All lanes: Western blot - Anti-TRIM8 antibody [EPR27965-6] (Anti-TRIM8 antibody [EPR27965-6] ab316149) at 1/1000 dilution
Lane 1: HeLa (human cervical adenocarcinoma epithelial cell) whole cell lysate at 20 µg with 5% NFDM/TBST
Lane 2: 293T (human embryonic kidney epithelial cell) whole cell lysate at 20 µg with 5% NFDM/TBST
Lane 3: NIH/3T3 (mouse embryonic fibroblast) whole cell lysate at 20 µg with 5% NFDM/TBST
Lane 4: PC-12 (rat adrenal gland pheochromocytoma cell) whole cell lysate at 20 µg with 5% NFDM/TBST
Lane 5: MCF7 (human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg with 5% NFDM/TBST
Lanes 6 - 7: T-47D (human ductal breast epithelial tumor epithelial cell) whole cell lysate at 20 µg with 5% NFDM/TBST
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Observed band size: 61 kDa
Exposure time: 180s
This data was developed using Anti-TRIM8 antibody [EPR27965-6] ab316149, the same antibody clone in a different buffer formulation.
Flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized HCT 116 (human colorectal carcinoma epithelial cell) cells labelling TRIM8 with Anti-TRIM8 antibody [EPR27965-6] ab316149 at 1/50 dilution (1 ug)/(Red) compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue).
Goat Anti-Rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081) at 1/5000 dilution was used as the secondary antibody.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com